GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer

Abstract

Background Triple-negative breast cancers (TNBCs), which lack receptors for estrogen, progesterone, and amplification of epidermal growth factor receptor 2, are highly aggressive. Consequently, patients diagnosed with TNBCs have reduced overall and disease-free survival rates compared to patients with other subtypes of breast cancer. TNBCs are characterized by the presence of cancer cells with mesenchymal properties, indicating that the epithelial to mesenchymal transition (EMT) plays a major role in the progression of this disease. The EMT program has also been implicated in chemoresistance, tumor recurrence, and induction of cancer stem cell (CSC) properties. Currently, there are no targeted therapies for TNBC, and hence, it is critical to identify the novel targets to treat TNBC. Methods A library of compounds was screened for their ability to inhibit EMT in cells with mesenchymal phenotype as assessed using the previously described Z-cad reporters. Of the several drugs tested, GSK3β inhibitors were identified as EMT inhibitors. The effects of GSK3β inhibitors on the properties of TNBC cells with a mesenchymal phenotype were assessed using qRT-PCR, flow cytometry, western blot, mammosphere, and migration and cell viability assays. Publicly available datasets also were analyzed to examine if the expression of GSK3β correlates with the overall survival of breast cancer patients. Results We identified a GSK3β inhibitor, BIO, in a drug screen as one of the most potent inhibitors of EMT. BIO and two other GSK3β inhibitors, TWS119 and LiCl, also decreased the expression of mesenchymal markers in several different cell lines with a mesenchymal phenotype. Further, inhibition of GSK3β reduced EMT-related migratory properties of cells with mesenchymal properties. To determine if GSK3β inhibitors target mesenchymal-like cells by affecting the CSC population, we employed mammosphere assays and profiled the stem cell-related cell surface marker CD44+/24− in cells after exposure to GSK3β inhibitors. We found that GSK3β inhibitors indeed decreased the CSC properties of cell types with mesenchymal properties. We treated cells with epithelial and mesenchymal properties with GSK3β inhibitors and found that GSK3β inhibitors selectively kill cells with mesenchymal attributes while sparing cells with epithelial properties. We analyzed patient data to identify genes predictive of poor clinical outcome that could serve as novel therapeutic targets for TNBC. The Wnt signaling pathway is critical to EMT, but among the various factors known to be involved in Wnt signaling, only the higher expression of GSK3β correlated with poorer overall patient survival. Conclusions Taken together, our data demonstrate that GSK3β is a potential target for TNBCs and suggest that GSK3β inhibitors could serve as selective inhibitors of EMT and CSC properties for the treatment of a subset of aggressive TNBC. GSK3β inhibitors should be tested for use i...

The inhibition of KDM2B promotes the differentiation of basal-like breast cancer cells via the posttranslational destabilization of SLUG

“…In agreement with earlier observations (Lee and Ro, 2015;Vijay et al, 2019), pharmacological inhibition of GSK3β resulted in SLUG downregulation in basal-like breast cancer cell lines and prevented EMT in cells treated with TGF-β. These observations suggest that inhibition of GSK3β drives mammary cell differentiation, and that it may be a promising strategy for the treatment of basallike breast cancer.…”

MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer

“…HME cells have been routinely used as a model system to study the oncogenic transformation of non-immortalised breast epithelial cells to immortalised transformed cancer cells. [25][26][27] Furthermore, HME cells lack expression of the oestrogen receptor (ER) and therefore provides the opportunity to model the development of ER-negative breast cancers. 28 A more recent study showed that the phenotype and cellular behaviour that emerged in a separate model of MYC expressing HME cells was very similar to that of MDA-MB-231 cells, a TNBC cell line.…”

Genome-wide DNA methylation and expression patterns of microRNAs in relation to breast cancer subtypes among American women of African and European ancestry

“…Various important metastasis-and cancer-related pathways were enriched, including cell cycle regulation, angiogenesis, EMT, and Wnt, TGFβ and ESR1-mediated signaling. Speci cally, we found that these miRNAs participate in these pathways through interactions with targets such as ESR1, GSK3β, MMP-2/-9, TGFβ, mTOR, SMAD4, c-Myc, HIF1α, and PI3KCA, some of which have been shown to regulate various signaling pathways and cellular functions in breast carcinogenesis (47)(48)(49)(50). These results suggest that these miRNAs target many key genes and work as a module, contributing to breast cancer phenotypic differences and aggressiveness.…”